<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/020C379B-65AA-4CC6-814B-2712D73AA213"><gtr:id>020C379B-65AA-4CC6-814B-2712D73AA213</gtr:id><gtr:name>Hepatitis C Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6D882B82-9FC2-468F-B0AC-082F6FDD7C96"><gtr:id>6D882B82-9FC2-468F-B0AC-082F6FDD7C96</gtr:id><gtr:name>Oncimmune</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BDFA256A-9A09-4221-BDF8-D0543F3EF453"><gtr:id>BDFA256A-9A09-4221-BDF8-D0543F3EF453</gtr:id><gtr:name>Gilead Sciences, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B99119E1-8DBD-4C1D-B03E-364724141FCE"><gtr:id>B99119E1-8DBD-4C1D-B03E-364724141FCE</gtr:id><gtr:name>Janssen Diagnostics</gtr:name><gtr:address><gtr:line1>Turnhoutsewig 30</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Experimental Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/020C379B-65AA-4CC6-814B-2712D73AA213"><gtr:id>020C379B-65AA-4CC6-814B-2712D73AA213</gtr:id><gtr:name>Hepatitis C Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6D882B82-9FC2-468F-B0AC-082F6FDD7C96"><gtr:id>6D882B82-9FC2-468F-B0AC-082F6FDD7C96</gtr:id><gtr:name>Oncimmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BDFA256A-9A09-4221-BDF8-D0543F3EF453"><gtr:id>BDFA256A-9A09-4221-BDF8-D0543F3EF453</gtr:id><gtr:name>Gilead Sciences, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B99119E1-8DBD-4C1D-B03E-364724141FCE"><gtr:id>B99119E1-8DBD-4C1D-B03E-364724141FCE</gtr:id><gtr:name>Janssen Diagnostics</gtr:name><gtr:address><gtr:line1>Turnhoutsewig 30</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E89C5F6C-3EB1-417F-943E-127C327DAEDD"><gtr:id>E89C5F6C-3EB1-417F-943E-127C327DAEDD</gtr:id><gtr:firstName>Eleanor</gtr:firstName><gtr:surname>Barnes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BDB5D794-7641-4061-AE49-34690217DB49"><gtr:id>BDB5D794-7641-4061-AE49-34690217DB49</gtr:id><gtr:firstName>Nicole</gtr:firstName><gtr:surname>Zitzmann</gtr:surname><gtr:orcidId>0000-0003-1969-4949</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EC9ADD61-F780-4960-92E8-D08B472E3E55"><gtr:id>EC9ADD61-F780-4960-92E8-D08B472E3E55</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:otherNames>Russell</gtr:otherNames><gtr:surname>Foster</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62D6FF4A-6D4E-4498-B003-169FF03D9DD6"><gtr:id>62D6FF4A-6D4E-4498-B003-169FF03D9DD6</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>Cooke</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9BE4E56D-F29C-4E33-8531-2E38A920C12A"><gtr:id>9BE4E56D-F29C-4E33-8531-2E38A920C12A</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Vickerman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E177C8BB-B945-4C3E-87AA-82C01E3143C4"><gtr:id>E177C8BB-B945-4C3E-87AA-82C01E3143C4</gtr:id><gtr:firstName>Alec</gtr:firstName><gtr:surname>Miners</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B9B2AE0C-DA98-4ED9-9B8A-3596CDA589A4"><gtr:id>B9B2AE0C-DA98-4ED9-9B8A-3596CDA589A4</gtr:id><gtr:firstName>Patricia</gtr:firstName><gtr:otherNames>Ann</gtr:otherNames><gtr:surname>Cane</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0FB60657-D3F7-4C78-A159-5912A4CCE119"><gtr:id>0FB60657-D3F7-4C78-A159-5912A4CCE119</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Francis</gtr:otherNames><gtr:surname>Dillon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AC598898-2621-408B-B5DC-3F99F0CB3462"><gtr:id>AC598898-2621-408B-B5DC-3F99F0CB3462</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>Kelvin</gtr:otherNames><gtr:surname>Ball</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9B847ED0-D2B1-494D-A537-43DA52723D39"><gtr:id>9B847ED0-D2B1-494D-A537-43DA52723D39</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Klenerman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AE9CD5A8-6930-446A-A0BC-7785B859B53E"><gtr:id>AE9CD5A8-6930-446A-A0BC-7785B859B53E</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Spencer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/224F438B-D9C4-4291-9A40-0AEFC75849FC"><gtr:id>224F438B-D9C4-4291-9A40-0AEFC75849FC</gtr:id><gtr:firstName>William</gtr:firstName><gtr:surname>Irving</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E08F7CF9-201C-4200-ADB0-8467A9989AF4"><gtr:id>E08F7CF9-201C-4200-ADB0-8467A9989AF4</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Holmes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CB18B11D-5FF0-498E-8676-369C54B769BF"><gtr:id>CB18B11D-5FF0-498E-8676-369C54B769BF</gtr:id><gtr:firstName>Emma</gtr:firstName><gtr:surname>Thomson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DF3A28D6-E406-4C88-89D4-DEC098A7BCEA"><gtr:id>DF3A28D6-E406-4C88-89D4-DEC098A7BCEA</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Simmonds</gtr:surname><gtr:orcidId>0000-0002-7964-4700</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/92EB47C3-A7C8-47C9-82FE-759E0D5DEBE0"><gtr:id>92EB47C3-A7C8-47C9-82FE-759E0D5DEBE0</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:otherNames>Alison</gtr:otherNames><gtr:surname>McKeating</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B281B6A0-C875-4C00-BC5E-EBE05C0740C8"><gtr:id>B281B6A0-C875-4C00-BC5E-EBE05C0740C8</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>guha</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3AE7FA06-CC94-4609-9CCA-B78EEA7B2B69"><gtr:id>3AE7FA06-CC94-4609-9CCA-B78EEA7B2B69</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>McLauchlan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D1992F8-8A54-4A8D-B49C-53C91D750EAF"><gtr:id>6D1992F8-8A54-4A8D-B49C-53C91D750EAF</gtr:id><gtr:firstName>Natasha</gtr:firstName><gtr:surname>Martin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0BC5F456-A992-4481-B519-92BD7768683C"><gtr:id>0BC5F456-A992-4481-B519-92BD7768683C</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Kellam</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/82274EEE-7284-448F-9C3A-723314B0B4AC"><gtr:id>82274EEE-7284-448F-9C3A-723314B0B4AC</gtr:id><gtr:firstName>Salim</gtr:firstName><gtr:surname>Khakoo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/93AFAB1F-230C-4C8A-AA50-38663891EE93"><gtr:id>93AFAB1F-230C-4C8A-AA50-38663891EE93</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Riley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK01532X%2F1"><gtr:id>841F7999-EC41-43FC-AE1F-D0069E507E55</gtr:id><gtr:title>Stratified Medicine to Optimise Treatment for Hepatitis C Virus Infection</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K01532X/1</gtr:grantReference><gtr:abstractText>Stratified Medicine is a type of personalised medicine where treatments are directed specifically at people who are most likely to respond to them, often using detailed information about individuals. We believe that the treatment of patients with hepatitis C virus (HCV) would benefit enormously from this approach. 

About 300,000 people in the UK are infected with HCV, only half of whom have been diagnosed as carrying the virus. The virus has a high tendency to persist as the body's immune system is usually unable to clear infection. HCV infects the liver, causing liver cirrhosis (scarring), liver failure and liver cancer. HCV exists in different genetic forms called genotypes. In the UK, most infections are caused by either genotype 1 or 3, which occur at about equal frequency. 

Treatment for HCV has consisted of two drugs interferon and ribavirin. Approximately half of patients receiving treatment respond and are successfully cured of infection. Until recently, no additional drugs were available to treat those who failed treatment. The number of people who develop severe liver disease from HCV is expected to continue to rise over the next two decades. Those who develop liver failure can be given a transplant but the transplanted organ is rapidly infected with the virus and often becomes diseased within a few years.

New drugs, which directly act against the virus (called DAAs), are being used in combination with interferon and ribavirin in NHS patients for the first time in the clinic in 2012. DAA drugs increase the cure rate to 70%. However, there are drawbacks: the drugs are very expensive costing in excess of &amp;pound;20,000 per patient; the virus can become resistant to new drugs, rendering them useless and increasing the frequency of resistant strains in the community; the first wave of new drugs are effective against genotype 1 but not genotype 3 strains; additional side effects can be associated with the new drugs, so that treatment may be stopped before the viru is eliminated.

We have developed a team of experts in the clinical care of HCV patients, who will work with HCV scientists, in partnership with industry. Combining expertise in this way should serve to benefit patients. The group is already working well together collecting blood samples and information from 10,000 people across the UK into a single bio-bank, supported by government infrastructure. We aim to assess the genetic make up of both the virus and the infected person. We will also look at the way in which the immune system responds to the virus, and measure protein markers in the blood. We will assess these in patients receiving therapy and also in those with serious liver disease to try to work out in advance who will develop further complications of their disease. A unique feature of our group will be the ability to draw all these strands together. 

We will develop new technologies so that we rapidly obtain the host and viral sequence in thousands of infected people. In this way we hope to improve treatment options for patients so that the right therapies are given to patients who are most likely to benefit from them. We will focus our efforts especially on HCV genotype 3, which is a particular problem in UK patients, and also on patients with more serious liver disease, who are more difficult to treat with the new therapies. Ultimately we hope to predict the likelihood of treatment response in individuals, and possibly through our investigations develop new therapies. This could bring considerable cost-savings to the NHS and means that drugs are given to HCV-infected people who are most likely to respond to them.</gtr:abstractText><gtr:technicalSummary>HCV infects 300,000 people within the UK and is an MRC priority research area. We have developed a flexible and dynamic UK wide consortium(STOP-HCV) that will use patient stratification to optimise treatment of infected patients. The consortium builds on existing cutting edge clinical and scientific expertise, in genuine partnership with industry, supported by NIHR infrastructure.
Our overarching aim is to define and develop a deeper understanding of patient strata and to develop prognostic models so that rational treatment strategies can be deployed. In a new era of novel Directly Acting Antiviral (DAA) therapies, treating only a subset of patients with DAA will cost the NHS an estimated &amp;pound;96 million/year with an expected overall treatment failure rate of 30%. Moreover, 40% of patients receiving DAAs would respond to current cheaper therapies. Therefore, refined patient stratification will be of enormous clinical and economic benefit. A focus of our program will be study of HCV genotype-3 infection, highly prevalent in the UK, with a characteristic clinical phenotype, and a high relapse rate with standard therapy. We will also focus on difficult-to-treat patient groups such as those with cirrhosis and those co-infected with HIV, where optimal management pathways will be of particular benefit in patients. 
Our consortium is underpinned by HCV Research UK, a network of 18 UK centres biobanking samples from 10,000 HCV infected patients, linked to a state-of-the-art clinical database. The consortium has been purposefully constructed to support rational enquiry and will be divided into integrated themes including cohort development, host and viral genomics, immune phenotyping and biomarker evaluation. The program is supported by health economic, methodological, statistical, and bioinformatics expertise. The STOP-HCV consortium draws together UK expertise in collaborative working to ensure stratification at a national level for the optimal treatment of patients with HCV</gtr:technicalSummary><gtr:potentialImpactText>The economic and societal impacts of our consortium will be far reaching:

Enhancing the quality of life, health and well- being: Our overarching aim is to use stratification to enhance clinical decision-making and thereby achieve maximum effectiveness and cost-effectiveness of therapeutic regimens for hepatitis C virus (HCV) infection. We also aim to understand disease mechanisms that define patient strata so that new rational therapeutic approaches can be developed and deployed. We will focus on patients that are difficult to treat with advanced disease, and those with genotype-3 infection a strain that is particularly common in the UK. To achieve this we have developed a consortium in partnership with industry that unites academics from different disciplines, and clinicians at the forefront of the field. Impact on society will be achieved through direct health benefits to the 300,000 patients infected with HCV within the UK, many of whom develop liver cirrhosis, liver failure and hepatocellular cancer.

Contributing towards evidence based policy-making: Through integration between scientists, clinicians, statisticians and health economics, our consortium will drive national guidelines for the treatment of HCV. 

Economic impacts: New directly acting antivirals (DAAs) are now available at a cost of &amp;gt;&amp;pound;20,000/treatment course. Treating only 1% of infected people will cost the NHS &amp;pound;96 million. With effective stratification these therapies will be given to those people most likely to obtain maximum benefit with direct economic savings to the NHS. 

Economic prosperity: 
Our program of work involves the identification and integrated analysis of host and viral genomic markers and other biomarkers of disease progression and treatment response. This work may enhance UK competitiveness and prosperity (i) through the commercialisation and exploitation of predictive models of clinical outcomes, (ii) the development of high throughput assays for in-vitro assays of drug resiance testing, and (iii) high throughput integrative genomics. (vi) innovative statistical methodology that may be commercially exploited.
Furthermore, New insights into disease biology may lead to the development of novel therapeutic avenues and early phase clinical studies. 
Our work will increase innovative research capacity within academic organisations that seek to develop new therapies and diagnostic tools. 

Industry: Our consortium has been developed in alignment with industry needs in the arenas of both HCV pharama and diagnostics, and the industrial sector will benefit directly from our consortium. 

Voluntary sector: The hepatitis C Trust, a charity run by patients for patients is represented on the STOP-HCV steering committee. One additional direct spin-off from the consortium will be an increased participation of UK patients in clinical trials - an area in which historically, the UK has performed very badly.

Technological advances: Society will also benefit through technological advances made within the strategic aims of the projects. This will include the deployment and high throughput of novel genetic sequencing technologies and integrative platforms for host and viral genomics, immune phenotyping, and biomarkers. 

Realistic time scales for benefits to be achieved is 5 years.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-09-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-09-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4168144</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hepatitis C Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Hepatitis C Trust-STOP-HCV</gtr:description><gtr:id>8981425F-5808-4656-8D53-DC5083869BC3</gtr:id><gtr:impact>Engagement with patient groups, patient perspective on clinical studies and policies related to STOP-HCV Consortium</gtr:impact><gtr:outcomeId>56df4e8a3f6092.26312783-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge and expertise</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge and expertise</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Merck-STOP-HCV</gtr:description><gtr:id>82072B53-6467-457F-B2DC-94A1609587D0</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:outcomeId>56df4d90799446.54831222-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge and expertise, provision of samples and data from relevant clinical studies</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge and expertise</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Social and Community Medicine</gtr:department><gtr:description>Health economics-STOP-HCV</gtr:description><gtr:id>0111A21E-60D6-41BF-B3E1-6D58B86DCB59</gtr:id><gtr:impact>Publication describing how HCV treatment should be prioritised in the era of new direct acting antiviral drugs</gtr:impact><gtr:outcomeId>56df55ee05d7b0.95905186-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janssen Diagnostics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Janssen-STOP-HCV</gtr:description><gtr:id>0B5F9590-64D4-40A2-AB56-A24A5C91B1A7</gtr:id><gtr:impact>Preliminary studies to Identify miRNA profiles associated with different stages of liver fibrosis completed.</gtr:impact><gtr:outcomeId>56df542e5dc218.64680615-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise, exploration of use of miRNA as a biomarker for liver disease progression</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC - University of Glasgow Centre for Virus Research</gtr:department><gtr:description>Glasgow - HCV NGS pilot</gtr:description><gtr:id>B5ACFB05-107F-45E9-B8B2-54BA0E5FF1BF</gtr:id><gtr:impact>This collaboration formed part of the STOP-HCV pilot HCV next generation sequencing study - an exercise to formally compare HCV next generation sequencing methods undertaken in different UK centres. Results of the pilot study have been accepted for presentation at the 2016 EASL Liver meeting (April) and a manuscript is under review at the Journal of Clinical Microbiology.</gtr:impact><gtr:outcomeId>56df07b2bb6f76.85406520-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples and data, sharing of knowledge and expertise</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge and expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nottingham Digestive Diseases Centre</gtr:department><gtr:description>Nottingham - STOP-HCV</gtr:description><gtr:id>84593CB2-A66C-43E9-A908-F0AD53D95DB9</gtr:id><gtr:impact>Development of STOP-HCV patient registry, establishment of STOP-HCV Cirrhosis Study (UKCRN, observational study)</gtr:impact><gtr:outcomeId>56df485aba8367.99393481-2</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge and expertise, data management support, provision of study coordination support</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge and expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Southampton-STOP-HCV</gtr:description><gtr:id>B2F2E4E2-15E7-4AB3-9F60-AAC8A4135080</gtr:id><gtr:impact>none to report to date</gtr:impact><gtr:outcomeId>56df5113400811.14329673-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Immunity and Infection</gtr:department><gtr:description>Birmingham-STOP-HCV</gtr:description><gtr:id>9492A83A-D4F6-44A3-B916-1F678F79F123</gtr:id><gtr:impact>none to report to date</gtr:impact><gtr:outcomeId>56df5053d0f935.37511112-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oncimmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>OncImmune-STOP-HCV</gtr:description><gtr:id>7FCEC512-60E6-4968-A626-5E715857C651</gtr:id><gtr:impact>Feasibility testing completed, panel of antigens developed to use for further development and phase 2 testing</gtr:impact><gtr:outcomeId>56df52a9d34d91.78331997-1</gtr:outcomeId><gtr:partnerContribution>R&amp;amp;D to develop a diagnostic test to detect hepatocellular cancer</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Public Health and Policy</gtr:department><gtr:description>Health economics-STOP-HCV</gtr:description><gtr:id>1B7E13BD-9B27-4D6A-9ADF-851B5B3C0BCF</gtr:id><gtr:impact>Publication describing how HCV treatment should be prioritised in the era of new direct acting antiviral drugs</gtr:impact><gtr:outcomeId>56df55ee05d7b0.95905186-2</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Dundee-STOP-HCV</gtr:description><gtr:id>7CE276DF-8F6E-4315-B9C8-AF66A4AAA5BA</gtr:id><gtr:impact>none to report to date</gtr:impact><gtr:outcomeId>56df51824d3f56.64014357-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gilead Sciences, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Gilead Sciences - Boson study</gtr:description><gtr:id>5CA98D17-E406-4BB6-8D70-13B141822879</gtr:id><gtr:impact>Clinical findings from the study were published in 2015 (Foster et al; Gastroenterology). The success of UK recruitment to this study resulted in an increased confidence by Pharma to undertake Phase 3 trials in hepatitis C within the UK. Two further studies have been initiated - Gilead ASTRAL-1 study, Merck C-ISLE study. 
Further publications describing joint host and viral genome association studies, from use of patient samples, have been listed elsewhere (Pedergnana et al)</gtr:impact><gtr:outcomeId>56df0cc4ab1605.49273278-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples and data from patients enrolled in the study</gtr:partnerContribution><gtr:piContribution>Intellectual input into protocol, recruitment of UK patients, analysis of samples and data from patients enrolled into the study</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Clinical Trials Unit (CTU)</gtr:department><gtr:description>Imperial - STOP-HCV-1</gtr:description><gtr:id>1A2209EB-DD4E-447F-9B09-128DEE80567B</gtr:id><gtr:impact>Trial in progress, actively recruiting patients</gtr:impact><gtr:outcomeId>56df4c18bc4340.84041660-2</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise, provision of samples and data from STOP-HCV-1 trial for analysis</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise, intellectual input into study protocol for STOP-HCV-1 trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial College Trust</gtr:department><gtr:description>Imperial - STOP-HCV-1</gtr:description><gtr:id>58EFB285-95A0-4135-8258-FCD847413DAA</gtr:id><gtr:impact>Trial in progress, actively recruiting patients</gtr:impact><gtr:outcomeId>56df4c18bc4340.84041660-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise, provision of samples and data from STOP-HCV-1 trial for analysis</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise, intellectual input into study protocol for STOP-HCV-1 trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PHE - HCV NGS pilot</gtr:description><gtr:id>B84B25FB-0BB7-4ED7-939E-89F699C36757</gtr:id><gtr:impact>This collaboration formed part of the STOP-HCV pilot HCV next generation sequencing study - an exercise to formally compare HCV next generation sequencing methods undertaken in different UK centres. Results of the pilot study have been accepted for presentation at the 2016 EASL Liver meeting (April) and a manuscript is under review at the Journal of Clinical Microbiology.</gtr:impact><gtr:outcomeId>56df086d8a30b4.98071359-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge and expertise</gtr:partnerContribution><gtr:piContribution>Provision of samples and data, sharing of knowledge and expertise</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Blizard Institute</gtr:department><gtr:description>QMUL-STOP-HCV</gtr:description><gtr:id>CE5933D1-C012-42C6-AAE2-214B4BB67ABD</gtr:id><gtr:impact>Boson study, Merck C-ISLE study</gtr:impact><gtr:outcomeId>56df569a52b473.67861321-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge &amp;amp; expertise</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge &amp;amp; expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infection and Population Health</gtr:department><gtr:description>UCL-HCV NGS pilot</gtr:description><gtr:id>BFFDE6FE-DEDF-46D7-A73A-C6BAE8C0650F</gtr:id><gtr:impact>This collaboration formed part of the STOP-HCV pilot HCV next generation sequencing study - an exercise to formally compare HCV next generation sequencing methods undertaken in different UK centres. Results of the pilot study have been accepted for presentation at the 2016 EASL Liver meeting (April) and a manuscript is under review at the Journal of Clinical Microbiology.</gtr:impact><gtr:outcomeId>56df06d36109b4.51806355-1</gtr:outcomeId><gtr:partnerContribution>Analysis of samples and data; sharing of knowledge and expertise</gtr:partnerContribution><gtr:piContribution>Access to samples and data; expertise and sharing of knowledge</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Microbiology and Infectious Diseases</gtr:department><gtr:description>Nottingham - STOP-HCV</gtr:description><gtr:id>B5DF2FB3-2C28-4401-B306-E736415F0B4E</gtr:id><gtr:impact>Development of STOP-HCV patient registry, establishment of STOP-HCV Cirrhosis Study (UKCRN, observational study)</gtr:impact><gtr:outcomeId>56df485aba8367.99393481-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge and expertise, data management support, provision of study coordination support</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge and expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BSCGT Public Engagement Event - Vaccines &amp; Infectious Disease (hosted stall)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8D4D2F59-FB9D-441C-B267-31FF89EC7D58</gtr:id><gtr:impact>This all-day event included a series of seminars and a 2hr exhibitor event at which STOP-HCV Consortium hosted a stall. ~100-200 delegates registered for the event, and the target audience was primarily secondary school children and the general public. There was a high level of interest in the stall, from both school children and the general public, and the feedback received will inform plans for future events.</gtr:impact><gtr:outcomeId>56dd78e4c7cf00.53263782</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio packages</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3F12D807-ADB9-4613-A50F-524C7AB60F40</gtr:id><gtr:impact>A series of radio packages produced by or involving JKB that were aired on BBC R4 and also BBC World Radio</gtr:impact><gtr:outcomeId>58c822cde55ca3.64416787</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Spotlight on CRN hepatitis C research - interview for website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>16DA04E4-5328-42A7-94D7-454A241F7E14</gtr:id><gtr:impact>Interview for NIHR CRN spotlight on hepatitis C research - published on CRN website</gtr:impact><gtr:outcomeId>56dd954a8d4349.80923505</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.crn.nihr.ac.uk/hepatology/about-hepatology-research/spotlight-on-hepatitis/researcher/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public event (hosted stall)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D590DF3E-447E-4934-93EB-B3BCBA805834</gtr:id><gtr:impact>Stall sparked questions and answers surrounding virology and personalised medicine

Positive feedback from attendees at the stall resulted in an invitation to host the stall at another public event (Oxford Open Doors)</gtr:impact><gtr:outcomeId>54633e7427d6d5.76164000</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.ndm.ox.ac.uk/cheltenham-science-festival-2014-2</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Liver Congress, EASL 2017 (Barcelona)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50D87B4C-7828-4C34-8F12-7786620F1342</gtr:id><gtr:impact>Registry grant presentation&amp;quot; Thursday 14 April 2016 from 12:00 to 13:30.</gtr:impact><gtr:outcomeId>58beb7994f8d82.34452957</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with Oxford Centre for Personalised Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2827644-5AF1-49E6-B9FC-287270AAAA4D</gtr:id><gtr:impact>An interview with the Centre for Personalised Medicine (St Anne's College, Oxford) regarding personalised medicine &amp;amp; STOP-HCV.</gtr:impact><gtr:outcomeId>58c6ad5d07e059.78766549</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.well.ox.ac.uk/cpm/prof-ellie-barnes-2</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NK cell workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F7D3DADF-DF02-478C-91B1-AFBA9A3A2A7D</gtr:id><gtr:impact>We had a presentation a poster presentation at the NK2017 meeting for the work.</gtr:impact><gtr:outcomeId>58a9835ae01307.01846043</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.nk2016.it</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Outreach Session</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>91AEF476-EBCE-4A8E-806A-93CDFAB017DB</gtr:id><gtr:impact>Virology outreach talk</gtr:impact><gtr:outcomeId>58c8224aaaf483.10651477</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public event (hosted stall)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DCD6B25A-83AB-4466-A734-D6FF3BF09276</gtr:id><gtr:impact>Stall sparked interest/further questions surounding virology and personalised medicine

Increased awareness for STOP-HCV project - new followers on twitter</gtr:impact><gtr:outcomeId>54633fdb617565.90718176</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>Oxford NIHR principle fellow award</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>EDD34BA9-981C-44A9-8745-CB34F8AFCA8E</gtr:id><gtr:outcomeId>56dec530445a84.66068524</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>57000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Global Challenges Research Fund</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6A5E8A5F-17FD-4E3D-A22C-A40B06D4688B</gtr:id><gtr:outcomeId>58c6a815ebc935.25288065</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>81000</gtr:amountPounds><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Big Data for Human Health Seed Grant</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Li Ka Shing Foundation</gtr:fundingOrg><gtr:id>74013057-EB4A-4F57-84CF-072D880AC066</gtr:id><gtr:outcomeId>56dd7db849a7f1.34885230</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>DPhil studentship-NHIC STOP-HCV</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4A29C6DB-92C7-475F-BA7C-C467A0E1007B</gtr:id><gtr:outcomeId>56dea1c3c940c1.20687221</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust</gtr:department><gtr:description>Nottingham BRU funds</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>1DCB0965-D19E-4E2F-97A3-83E2709435EB</gtr:id><gtr:outcomeId>54637f2cec2f85.50165099</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Efficacy &amp;amp; Mechanism Evaluation (EME) programme</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>284D4D7E-D504-4612-8F33-39F553100A4F</gtr:id><gtr:outcomeId>56dd8d0eda7d93.16274723</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2022-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>18B9BFA6-661B-4E49-9558-4A425181DA53</gtr:id><gtr:outcomeId>58c64a2bc1e025.72988672</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>62000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Institutional Strategic Support Fund</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>CDB2F0AC-DDE5-4C90-BF7B-6A49B09E9EF0</gtr:id><gtr:outcomeId>58c6a4bd81fed0.63671992</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Large phase 3 study of patients with geno 3a HCV treated with sofosbuvir integrated with STOP-HCV</gtr:description><gtr:id>175E9361-E5DD-4359-B607-27445495610F</gtr:id><gtr:impact>Largest phase-3 hep C study in the UK-major benefits to patients and the economy</gtr:impact><gtr:outcomeId>54638061c58bb6.88406158</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Boson study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Drugs being used - VIEKIRAX, EXVIERA (Abbvie) and HARVONI (Gilead) - are licensed for use in the UK</gtr:description><gtr:id>B8670B2C-95D1-41A0-A4F1-BAC774B3F4BE</gtr:id><gtr:impact>Currently recruiting for trial - expected impact will be an improved, stratified approach to short course all-oral drug treatment for HCV infected patients with mild liver disease.</gtr:impact><gtr:outcomeId>56dd9e0522eeb0.81095295</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>STOP-HCV-1</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A database containing an anonymised, searchable listing of all patients whose samples have been analysed within STOP-HCV studies</gtr:description><gtr:id>4E904392-68AD-4904-B7F1-4847E0208337</gtr:id><gtr:impact>This registry allows STOP-HCV researchers to easily identify and prioritise relevant sub-groups of patients for future analyses</gtr:impact><gtr:outcomeId>56dd9ad73987e7.47737434</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>STOP-HCV patient registry</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://stop-hcv.nottingham.ac.uk</gtr:url></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>An online resource for the analysis of HCV sequence data.</gtr:description><gtr:id>F71E6532-40B6-4F13-B202-94152441CF36</gtr:id><gtr:impact>STOP-HCV is working closely with the team at the MRC-CVR in Glasgow to implement HCV-GLUE as a tool for the community (for both researchers and clinicians).</gtr:impact><gtr:outcomeId>58c6b65f57dc53.21580237</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HCV-GLUE</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://hcv.glue.cvr.ac.uk/#home</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Statistical methods developed in order to perform joint host and pathogen genome wide association analysis</gtr:description><gtr:id>F2A5C968-54BD-4973-A73E-503C70A29671</gtr:id><gtr:impact>To be determined</gtr:impact><gtr:outcomeId>56dd997f063896.93368631</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Statistical methods for joint host and viral genome association analysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>NGS for ful length HCV sequencing</gtr:description><gtr:id>AA4C8FAB-A42A-4797-B314-0EA6460FFE78</gtr:id><gtr:impact>The first tool for high throughput HCV sequencing</gtr:impact><gtr:outcomeId>54638167322ec3.29365781</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>NGS for HCV</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The STOP-HCV consortium has successfully established a hepatitis C virus (HCV) replicon system to measure the replication/fitness of HCV in vitro. The replicon system provides a valuable tool for monitoring the susceptibility and resistance of a wide range of HCV genotypes to direct-acting antiviral drugs, and determining the relevance of viral SNPs identified in vivo.</gtr:description><gtr:id>970CF123-B788-4312-9B35-917D8F5506D7</gtr:id><gtr:impact>The system is currently being used to assess the impact, and relevance, of baseline HCV resistance associated substitutions on treatment outcome. The initial focus has been with the drugs sofosbuvir and daclatisvir, but studies are being extended to include the most recent generation of licensed HCV direct-acting antiviral drugs.</gtr:impact><gtr:outcomeId>58c6b3d54775c1.59860134</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>In vitro HCV replicon system</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6EFA0EEE-6E09-44CA-B3D8-30EF3C196F37</gtr:id><gtr:title>Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e5447a20e5237a088883e190d3b9dae"><gtr:id>5e5447a20e5237a088883e190d3b9dae</gtr:id><gtr:otherNames>Bonsall D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>56d84584cb4de0.62995936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF023D39-1F16-4A07-97B2-2CD33155CFCA</gtr:id><gtr:title>Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa56070c948c0fb966fe86c46b8bd5f7"><gtr:id>aa56070c948c0fb966fe86c46b8bd5f7</gtr:id><gtr:otherNames>Foster GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56d8380ee5a8d5.99914806</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E610814F-0871-4B5A-9095-3CDA5FE37203</gtr:id><gtr:title>Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39e0393fc48fdd4da51e569bcdfa0f75"><gtr:id>39e0393fc48fdd4da51e569bcdfa0f75</gtr:id><gtr:otherNames>Stelma F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a2fd650999d96.39117818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CBA0D0B-4DA8-46E2-812D-07F48DFD57F6</gtr:id><gtr:title>Multiple reaction monitoring and multiple reaction monitoring cubed based assays for the quantitation of apolipoprotein F.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a93647d799d53d5111001b3b241fdab"><gtr:id>1a93647d799d53d5111001b3b241fdab</gtr:id><gtr:otherNames>Kumar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>58c92abed540c1.11856619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31630F4C-EC8C-4EF1-9007-09925A2EB397</gtr:id><gtr:title>Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5683d528d5840ee74c0f63b7fed1b7c"><gtr:id>d5683d528d5840ee74c0f63b7fed1b7c</gtr:id><gtr:otherNames>Platt L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58c6c081ef17a2.61381671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5B11AA4-FD18-4927-99F5-FA9693120CFB</gtr:id><gtr:title>'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8dbeab04d42a54299e2b83f8b0ba1be"><gtr:id>f8dbeab04d42a54299e2b83f8b0ba1be</gtr:id><gtr:otherNames>Bucci C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_16395_25_23486666</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B968BDB-A2CB-4650-AA73-5B1325C18215</gtr:id><gtr:title>Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f910cfd938f25e6e6e45c466f2c7dc1"><gtr:id>1f910cfd938f25e6e6e45c466f2c7dc1</gtr:id><gtr:otherNames>Ansari MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5a6f56c3670b71.81114259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F4E2A11-F7F4-4EF3-A7A6-CFF78B86FCAA</gtr:id><gtr:title>Genome-To-Genome Virus-Host Analysis Reveals HCV Genotype 3 Viral Polymorphisms Linked Viral Load and to Host HLA Class-I/II and IL28B Alleles</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6c05f4bd7a3bd602a59e968301489f8"><gtr:id>c6c05f4bd7a3bd602a59e968301489f8</gtr:id><gtr:otherNames>Azim Ansari M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58be8c7c870b59.76848989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E507723C-4918-4AC4-A3C6-07C4634B3E92</gtr:id><gtr:title>MAIT cells are activated during human viral infections.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd9c5d3ad67e5b8adc8f4409ebdea785"><gtr:id>fd9c5d3ad67e5b8adc8f4409ebdea785</gtr:id><gtr:otherNames>van Wilgenburg B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58bd40e9b97e37.66281318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87ED99AE-1417-4EF1-BB32-FE807DCE89F1</gtr:id><gtr:title>Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/640066d44c0c0ff681f127fcc480dff3"><gtr:id>640066d44c0c0ff681f127fcc480dff3</gtr:id><gtr:otherNames>Cheung MCM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58c6c081b93534.36943738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0661DD82-C6AD-4FED-BCD8-C51E434A772F</gtr:id><gtr:title>Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e0758eeac82d30f843648ee461fcdb2"><gtr:id>4e0758eeac82d30f843648ee461fcdb2</gtr:id><gtr:otherNames>Iles JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>56cf0446ccc364.63601831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA7A455B-669E-4DCC-95F9-0C6BF099C214</gtr:id><gtr:title>PTH-092&amp;nbsp;Discovery and quantitation of novel liver fibrosis biomarkers using proteomics</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee8e47d5ca2ed34b98bf9e47c41be102"><gtr:id>ee8e47d5ca2ed34b98bf9e47c41be102</gtr:id><gtr:otherNames>Gangadharan B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d83b33441586.13723445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73611C28-EF03-49CD-A80D-4A8976373826</gtr:id><gtr:title>Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54be9e9a7aa2edcdde2d87e82809b337"><gtr:id>54be9e9a7aa2edcdde2d87e82809b337</gtr:id><gtr:otherNames>Afik S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5a6f2e1a893a70.52248544</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C715097-F645-4104-90DF-75F1DBDCF254</gtr:id><gtr:title>Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cc1a629d431ece4a70f4e2339867e5a"><gtr:id>4cc1a629d431ece4a70f4e2339867e5a</gtr:id><gtr:otherNames>da Silva Filipe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a8d6b2c5a29b7.91580738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81089EE8-4A64-44F2-901D-A47509DE9EE6</gtr:id><gtr:title>Joint whole-genome analysis of associations between host and hepatitis C virus diversity in a patient cohort.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2623634369ddffd5f2c081a495aba8"><gtr:id>1e2623634369ddffd5f2c081a495aba8</gtr:id><gtr:otherNames>Pedergnana V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dd9218740bc4.63881848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A9AA7D9-40F7-47A8-B92A-79EADB6A560F</gtr:id><gtr:title>Screening and treatment for hepatitis C: a balanced perspective.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>56cf0447398c32.73180600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE552D33-51A0-47B1-9F66-0A97B2CBA7F0</gtr:id><gtr:title>ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens.</gtr:title><gtr:parentPublicationTitle>F1000Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e5447a20e5237a088883e190d3b9dae"><gtr:id>5e5447a20e5237a088883e190d3b9dae</gtr:id><gtr:otherNames>Bonsall D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-1402</gtr:issn><gtr:outcomeId>56d847771c2be5.87628688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04FA7D9F-38BF-4568-AECC-81ADEA3AF7FB</gtr:id><gtr:title>Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecf7f4024cf29422d05720b65f0cab51"><gtr:id>ecf7f4024cf29422d05720b65f0cab51</gtr:id><gtr:otherNames>van de Ven N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>58c6c0824f8b03.48113316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6D76686-4246-47E0-BE54-4927DBC348B9</gtr:id><gtr:title>The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0b66f564df893595d8704aa5ecab3ed"><gtr:id>d0b66f564df893595d8704aa5ecab3ed</gtr:id><gtr:otherNames>Stanaway J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d35d4844526.42645596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13D6FFE2-29D2-4B86-9646-28580A11B4A3</gtr:id><gtr:title>Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe12458af70f67e6890a66d553f3c8ee"><gtr:id>fe12458af70f67e6890a66d553f3c8ee</gtr:id><gtr:otherNames>Mora-Peris B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56cf0447126634.42668040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37DECB80-387B-4EA1-A3E8-0F8F7523DE19</gtr:id><gtr:title>Global distribution and prevalence of hepatitis C virus genotypes.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b908e6ceb5ed4e4f707b25951b2ffc24"><gtr:id>b908e6ceb5ed4e4f707b25951b2ffc24</gtr:id><gtr:otherNames>Messina JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5463262d7d2705.86760248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCFB278D-5FB0-4175-A6AB-77C159C8DCFF</gtr:id><gtr:title>Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75f235afe3976f611342d0b14cd3bb2f"><gtr:id>75f235afe3976f611342d0b14cd3bb2f</gtr:id><gtr:otherNames>Walker AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>5a8c2cf90310d6.09586454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9E86AFA-F406-45F2-B972-86CEF7E42772</gtr:id><gtr:title>Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa56070c948c0fb966fe86c46b8bd5f7"><gtr:id>aa56070c948c0fb966fe86c46b8bd5f7</gtr:id><gtr:otherNames>Foster GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58c6c082229e36.55350653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD3FC2D3-5E7B-4FD3-AB6B-EA2F113506F7</gtr:id><gtr:title>Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0e6f2f52b3aecc428327496834decf9"><gtr:id>f0e6f2f52b3aecc428327496834decf9</gtr:id><gtr:otherNames>Smith D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a8c2dbaabde08.85147255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>224D0745-8A85-446F-B6EA-0D18198AB090</gtr:id><gtr:title>PHYLOSCANNER: Inferring Transmission from Within- and Between-Host Pathogen Genetic Diversity.</gtr:title><gtr:parentPublicationTitle>Molecular biology and evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42852496542127ea0f5841f4e623eb04"><gtr:id>42852496542127ea0f5841f4e623eb04</gtr:id><gtr:otherNames>Wymant C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0737-4038</gtr:issn><gtr:outcomeId>5aa7a30e6ec967.34577158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>067CD581-B35C-4B5E-A9E6-2DE221C90146</gtr:id><gtr:title>Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdde3fb842addf09615e00c788ae8cd5"><gtr:id>bdde3fb842addf09615e00c788ae8cd5</gtr:id><gtr:otherNames>Witteveldt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5759491c181409.33595909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B3E6584-F764-4FDB-8D76-3D24881F52EF</gtr:id><gtr:title>Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56dd7bdf095a29.42778603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B155E17-1631-4BE9-A0E3-4C8CEEBDF8C5</gtr:id><gtr:title>Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f184e1a5169e970ee2668a72321eb0c"><gtr:id>2f184e1a5169e970ee2668a72321eb0c</gtr:id><gtr:otherNames>Thomson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>58bd4188015e73.32343766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED4C30F4-CF16-4056-85B8-A688082A4E88</gtr:id><gtr:title>Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2623634369ddffd5f2c081a495aba8"><gtr:id>1e2623634369ddffd5f2c081a495aba8</gtr:id><gtr:otherNames>Pedergnana V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56dd92f1060701.66009672</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K01532X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>